EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure



Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure



Blood 127(13): 1656-1665



Hepatic veno-occlusive disease (VOD), also called sinusoidal obstruction syndrome (SOS), is a potentially life-threatening complication of hematopoietic stem cell transplantation (HSCT). Untreated hepatic VOD/SOS with multi-organ failure (MOF) is associated with >80% mortality. Defibrotide has shown promising efficacy treating hepatic VOD/SOS with MOF in phase 2 studies. This phase 3 study investigated safety and efficacy of defibrotide in patients with established hepatic VOD/SOS and advanced MOF. Patients (n = 102) given defibrotide 25 mg/kg per day were compared with 32 historical controls identified out of 6867 medical charts of HSCT patients by blinded independent reviewers. Baseline characteristics between groups were well balanced. The primary endpoint was survival at day +100 post-HSCT; observed rates equaled 38.2% in the defibrotide group and 25% in the controls (23% estimated difference; 95.1% confidence interval [CI], 5.2-40.8;P= .0109, using a propensity-adjusted analysis). Observed day +100 complete response (CR) rates equaled 25.5% for defibrotide and 12.5% for controls (19% difference using similar methodology; 95.1% CI, 3.5-34.6;P= .0160). Defibrotide was generally well tolerated with manageable toxicity. Related adverse events (AEs) included hemorrhage or hypotension; incidence of common hemorrhagic AEs (including pulmonary alveolar [11.8% and 15.6%] and gastrointestinal bleeding [7.8% and 9.4%]) was similar between the defibrotide and control groups, respectively. Defibrotide was associated with significant improvement in day +100 survival and CR rate. The historical-control methodology offers a novel, meaningful approach for phase 3 evaluation of orphan diseases associated with high mortality. This trial was registered at www.clinicaltrials.gov as #.

(PDF emailed within 0-6 h: $19.90)

Accession: 058541908

Download citation: RISBibTeXText

PMID: 26825712

DOI: 10.1182/blood-2015-10-676924



Related references

Defibrotide is effective in the treatment of severe veno-occlusive disease and multi-system organ failure post stem cell transplantation Results of a phase II, multicenter, randomized Study. Blood 102(11): 193a, November 16, 2003

Defibrotide Appears Effective and Safe in a Phase II, Randomized Study of Patients with Severe Veno-Occlusive Disease and Multi-System Organ Failure Post Stem Cell Transplantation. Blood 100(11): Abstract No 414, November 16, 2002

Multi-institutional phase II, randomized dose finding study of defibrotide in patients with severe veno-occlusive disease and multi-system organ failure post stem cell transplantation Promising response rate without significant toxicity in a high risk population. Blood 98(11 Part 1): 853a, November 16, 2001

Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 100(13): 4337-4343, 2002

Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biology of Blood and Marrow Transplantation 16(7): 1005-1017, 2011

The budget impact and cost-effectiveness of defibrotide for treatment of veno-occlusive disease with multi-organ dysfunction in patients post-hematopoietic stem cell transplant. Journal of Medical Economics 20(5): 453-463, 2016

Pooled Treatment Analysis of Pediatric Patients with Defibrotide for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Multi-Organ Dysfunction Following Hematopoietic Stem Cell Transplant. Biology of Blood and Marrow Transplantation 22(3): S188-S189, 2016

Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease. Therapeutic Advances in Hematology 3(4): 253-265, 2013

Hemorrhagic complications after treatment with defibrotide in a case of severe veno-occlusive disease. Medicina Clinica 118(13): 518-519, 2002

Veno-occlusive disease and multi-organ failure following actinomycin-D treatment Clinical characteristics and predictive factors. JPGN 31(Supplement 2): S51, 2000

Treatment of severe veno-occlusive disease with defibrotide Compassionate use results in efficacy without significant toxicity in a high risk population. Blood 90(10 SUPPL 1 PART 1): 252A, Nov 15, 1997

Successful treatment of severe veno-occlusive disease of the liver with combination tissue plasminogen activator and defibrotide A case report. British Journal of Haematology 105(SUPPL 1): 57, April, 1999

Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 92(3): 737-744, 1998

Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet 379(9823): 1301-1309, 2012

Defibrotide for Prophylaxis of Hepatic Veno-Occlusive Disease in Pediatric Hematopoietic Stem Cell Transplantation: Subanalysis Data from an Open-Label, Phase III, Randomized Trial. Biology of Blood and Marrow Transplantation 22(3): S25-S26, 2016